ARTICLE | Deals
BeiGene picks iPS cells for its move into cell therapies via Shoreline deal
BeiGene enters cell therapy via deal with San Diego iPS cell company for $45M up front
June 10, 2021 12:42 AM UTC
BeiGene is kicking off its move into cell therapies through a collaboration with Shoreline that brings access to induced pluripotent stem cell-derived NK cell therapies — a modality that’s proven itself in recent clinical trials.
The companies teamed up to develop and commercialize iPS cell-derived CAR NK cells against four undisclosed targets, some of which have already been selected, in a deal that brings Shoreline Biosciences Inc. $45 million up front plus undisclosed R&D funding, milestones and royalties...